M Słomkowski

935 total citations · 1 hit paper
23 papers, 628 citations indexed

About

M Słomkowski is a scholar working on Psychiatry and Mental health, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, M Słomkowski has authored 23 papers receiving a total of 628 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Psychiatry and Mental health, 5 papers in Hematology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in M Słomkowski's work include Dementia and Cognitive Impairment Research (5 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Schizophrenia research and treatment (4 papers). M Słomkowski is often cited by papers focused on Dementia and Cognitive Impairment Research (5 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Schizophrenia research and treatment (4 papers). M Słomkowski collaborates with scholars based in United States, Denmark and Poland. M Słomkowski's co-authors include Clifford R. Jack, Peter C. O’Brien, Yun Xu, Keith Stewart, Ruitao Cha, S. Gracon, Toni M. Hoover, David S. Knopman, Ronald C. Petersen and Maria Shiung and has published in prestigious journals such as Neurology, Journal of Affective Disorders and Journal of Alzheimer s Disease.

In The Last Decade

M Słomkowski

23 papers receiving 606 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia

2023 61 citations Daniel Lee, M Słomkowski et al. JAMA Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M Słomkowski United States	8	296	218	111	104	94	23	628
Benjamin Lam Canada	12	245 0.8×	231 1.1×	154 1.4×	51 0.5×	29 0.3×	32	702
Jeanette Günther United States	7	361 1.2×	229 1.1×	124 1.1×	46 0.4×	30 0.3×	14	604
Małgorzata Maciukiewicz Canada	18	201 0.7×	63 0.3×	77 0.7×	69 0.7×	114 1.2×	46	762
Diana Truran‐Sacrey United States	11	312 1.1×	283 1.3×	217 2.0×	41 0.4×	18 0.2×	20	720
Christopher Clyde United States	8	528 1.8×	97 0.4×	35 0.3×	147 1.4×	117 1.2×	9	873
Nikolaus Freymann Germany	10	120 0.4×	67 0.3×	150 1.4×	86 0.8×	34 0.4×	12	511
Karen C. Holdridge United States	14	476 1.6×	426 2.0×	120 1.1×	144 1.4×	17 0.2×	29	826
Everard G.B. Vijverberg Netherlands	16	355 1.2×	374 1.7×	79 0.7×	60 0.6×	32 0.3×	56	785
Marion Ortner Germany	15	332 1.1×	308 1.4×	242 2.2×	28 0.3×	28 0.3×	45	742
Lena McCue United States	10	413 1.4×	418 1.9×	298 2.7×	31 0.3×	25 0.3×	12	823

Countries citing papers authored by M Słomkowski

Since Specialization

Citations

This map shows the geographic impact of M Słomkowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Słomkowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Słomkowski more than expected).

Fields of papers citing papers by M Słomkowski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M Słomkowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Słomkowski. The network helps show where M Słomkowski may publish in the future.

Co-authorship network of co-authors of M Słomkowski

This figure shows the co-authorship network connecting the top 25 collaborators of M Słomkowski. A scholar is included among the top collaborators of M Słomkowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Słomkowski. M Słomkowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rothman, Brian, M Słomkowski, A. John Rush, et al.. (2025). A digital therapeutic (CT-152) as adjunct to antidepressant medication: A phase 3 randomized controlled trial (the Mirai study). Journal of Affective Disorders. 388. 119409–119409. 3 indexed citations

Shah, Alpesh, Pamela L. Sheridan, Dalei Chen, et al.. (2025). Safety and Tolerability of Brexpiprazole in Participants with Agitation Associated with Dementia due to Alzheimer’s Disease: Pooled Analysis of Three Randomized Trials and an Extension Trial. CNS Drugs. 39(10). 1011–1023. 2 indexed citations

Shah, Alpesh, Dalei Chen, Zhen Zhang, et al.. (2024). Efficacy and Safety of Brexpiprazole in Patients with Agitation Associated with Dementia Due to Alzheimer's Disease Analyzed by Presence or Absence of Baseline Psychosis: A Pooled Analysis. American Journal of Geriatric Psychiatry. 32(4). S94–S94. 1 indexed citations

Grossberg, George T., Daniel J. Lee, M Słomkowski, et al.. (2024). Safety, Tolerability, and Efficacy of Brexpiprazole for the Treatment of Agitation Associated with Dementia Due to Alzheimer’s Disease: A 12-week Extension Trial (P11-9.011). Neurology. 102(17_supplement_1). 1 indexed citations

Rothman, Brian, M Słomkowski, A. John Rush, et al.. (2024). Evaluating the Efficacy of a Digital Therapeutic (CT-152) as an Adjunct to Antidepressant Treatment in Adults With Major Depressive Disorder: Protocol for the MIRAI Remote Study. JMIR Research Protocols. 13. e56960–e56960. 6 indexed citations

Słomkowski, M, et al.. (2024). Brexpiprazole for the treatment of agitation associated with dementia due to Alzheimer's disease: A 12-week, active-treatment, extension trial. Journal of Alzheimer s Disease. 102(2). 520–529. 7 indexed citations

Grossberg, George T., Daniel Lee, M Słomkowski, et al.. (2023). Efficacy, Safety and Tolerability of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. American Journal of Geriatric Psychiatry. 31(3). S99–S100. 2 indexed citations

Lee, Daniel, M Słomkowski, Nanco Hefting, et al.. (2023). Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia. JAMA Neurology. 80(12). 1307–1307. 61 indexed citations breakdown →

Grossberg, George T., Eva Kohegyi, Mette Krog Josiassen, et al.. (2019). Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials. American Journal of Geriatric Psychiatry. 28(4). 383–400. 95 indexed citations

10.

Dyck, Christopher H. van, Carl Sadowsky, Kevin Booth, et al.. (2016). VANUTIDE CRIDIFICAR (ACC-001) AND QS-21 ADJUVANT IN INDIVIDUALS WITH EARLY ALZHEIMER’S DISEASE: AMYLOID IMAGING POSITRON EMISSION TOMOGRAPHY AND SAFETY RESULTS FROM A PHASE 2 STUDY. The Journal of Prevention of Alzheimer s Disease. 3(2). 1–10. 27 indexed citations

11.

Preskorn, Sheldon, et al.. (2011). How Adaptive Trial Designs can Increase Efficiency in Psychiatric Drug Development: A Case Study.. PubMed. 8(7). 26–34. 7 indexed citations

12.

Szczepanik, Andrzej B, A. Sikorska, M Słomkowski, & L Konopka. (2007). The use of vinca alkaloids in preparation for splenectomy of corticosteroid refractory chronic immune thrombocytopenic purpura patients. International Journal of Laboratory Hematology. 29(5). 347–351. 16 indexed citations

13.

Pande, Atul C., Douglas E. Feltner, James W. Jefferson, et al.. (2004). Efficacy of the Novel Anxiolytic Pregabalin in Social Anxiety Disorder. Journal of Clinical Psychopharmacology. 24(2). 141–149. 131 indexed citations

14.

Sikorska, A., M Słomkowski, Krystyna Maślanka, L Konopka, & T Górski. (2004). The use of vinca alkaloids in adult patients with refractory chronic idiopathic thrombocytopenia. Clinical & Laboratory Haematology. 26(6). 407–411. 18 indexed citations

15.

Słomkowski, M, et al.. (2004). B cells CD19+ in patients with B-cell chronic lymphocytic leukaemia and autoimmune haemolytic anaemia. Clinical & Laboratory Haematology. 26(6). 385–389. 1 indexed citations

16.

Feltner, Douglas E., Mark H. Pollack, J. Davidson, et al.. (2000). A placebo-controlled, double-blind study of pregabalin treatment of social phobia: Outcome and predictors of response. European Neuropsychopharmacology. 10. 344–345. 9 indexed citations

17.

Słomkowski, M, et al.. (1991). [Analysis of pregnancy, labor, child development and disease course in women with Hodgkin's disease].. PubMed. 21(1). 72–80. 2 indexed citations

18.

Słomkowski, M, et al.. (1991). [Treatment of low-malignancy lymphomas by spleen irradiation].. PubMed. 21(1). 85–91. 2 indexed citations

19.

Górski, Andrzej, et al.. (1983). Immunoregulatory factors controlling terminal differentiation of malignant B-lymphocytes. Immunology Letters. 6(6). 311–315. 3 indexed citations

20.

Michalak, T.I., et al.. (1983). Acute myeloblastic leukemia in patients with multiple myeloma.. PubMed. 14(1-2). 21–9. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact